Discovery of a novel and selective Indoleamine 2,3-Dioxygenase (IDO-1) inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and its characterization as a potential clinical candidate
Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment. IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function. As such, IDO-1 is a nexus f...
Main Authors: | Crosignani, S, Bingham, P, Bottemanne, P, Cannelle, H, Cauwenberghs, S, Cordonnier, M, Dalvie, D, Deroose, F, Feng, JL, Gomes, B, Greasley, S, Kaiser, SE, Kraus, M, Négrerie, M, Maegley, K, Miller, N, Murray, BW, Schneider, M, Soloweij, J, Stewart, AE, Tumang, J, Torti, VR, Van Den Eynde, B, Wythes, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Chemical Society
2017
|
Similar Items
-
Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy
by: Gomes, B, et al.
Published: (2018) -
Rational design of indoleamine 2,3-dioxygenase inhibitors.
by: Röhrig, U, et al.
Published: (2010) -
Contribution of indoleamine 2,3-dioxygenase in preeclampsia
by: Mona F.M El-Karn, et al.
Published: (2016-01-01) -
Indoleamine 2,3-dioxygenase in endometriosis
by: Hui-Li Yang, et al.
Published: (2019-01-01) -
Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes.
by: Orabona, C, et al.
Published: (2018)